RBC10
目录号 : GC66001
RBC10 是一种抗癌剂。RBC10 抑制 Ral 与其效应器 RALBP1 的结合。RBC10 还抑制 Ral 介导的鼠胚胎成纤维细胞扩散和人癌细胞系的非贴壁依赖性生长。
Cas No.:362503-73-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
RBC10 is an anti-cancer agent. RBC10 inhibits the binding of Ral to its effector RALBP1. RBC10 also inhibits Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines[1].
| Cas No. | 362503-73-9 | SDF | Download SDF |
| 分子式 | C24H25ClN2O2 | 分子量 | 408.92 |
| 溶解度 | DMSO : 125 mg/mL (305.68 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4455 mL | 12.2273 mL | 24.4547 mL |
| 5 mM | 0.4891 mL | 2.4455 mL | 4.8909 mL |
| 10 mM | 0.2445 mL | 1.2227 mL | 2.4455 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Ranking based formula optimization, quality investigation, and real-time shelf-life prediction of ready-to-eat ricebean ( Vigna umbellata) curry
J Food Sci Technol 2022 Nov;59(11):4390-4404.PMID:PMC9525507DOI:10.1007/s13197-022-05519-9.
Ricebean (Vigna umbellata) is an underutilized bean of South and South-East Asia, was exploited to formulate the ready-to-eat curry by using thermal processing technology. Eleven types of RTE ricebean curries (RBCs) namely RBC1, RBC2, RBC3, RBC4, RBC5, RBC6, RBC7, RBC8, RBC9, RBC10, RBC11 were developed by varying the proportion of tomato paste, onion paste, and coriander powder after thermal processing at 121 °C (15 psi) for 20 min. Out of these, the best quality curry was selected based on the total product ranking score (TPRS) which was calculated from the curry quality parameters such as consistency, pH, loss due to sorption onto the inner surface of the retort pouch (LOSS), and sensory (overall acceptability-OAA). Among the curries, RBC2 secured the highest value of TPRS, named it as RTE-RBC and was used to study the physico-chemical, textural, nutritional, microbial, sensory parameters and storage stability. The DPPH-antioxidant activity of RTE-RBC was 2.47 µM BHA/g which was due to the presence of bioactive phytochemicals such as polyphenol, flavonoids, lycopene, gingerol, ɣ-Oryzanol, and capsaicin. It was observed that the in-vitro protein/carbohydrate digestibility, in-vitro calcium bioavailability and real-time shelf-life (predicted) of RTE-RBC were 85%, 54%, and one year, respectively.
The Reactive Bounding Coefficient as a Measure of Horizontal Reactive Strength to Evaluate Stretch-Shortening Cycle Performance in Sprinters
J Hum Kinet 2020 Jul 21;73:45-55.PMID:32774536DOI:10.2478/hukin-2020-0003.
Plyometric exercises such as drop jumping and bounding offer athletes a substantiated means of enhancing athletic performance. Between the two exercises, reactive measurement using bounding (reactive bounding coefficient [RBC]) has received scant attention within the domain of training and conditioning. Therefore, this study aimed to identify the viability of utilising a speed-bounding exercise to assess horizontal reactive strength. Eleven young, male elite sprinters (age: 17.8 ± 1.3 yr; body height: 1.72 ± 0.06 m; body mass: 66.05 ± 6.10 kg; best 100 m sprint time: 10.77 ± 0.32 s) were tested for static jumps (SJ), drop jumps (DJ), 10 speed-bounding (RBC10), and 50 m sprint performance. Between-group comparisons based on sprint ability (fast [FSG] vs. slow [SSG] sprint-group) and correlation coefficients were computed subsequently. The FSG (n = 5; 50 m time: 5.82 ± 0.11 s; RBC10: 7.46 ± 0.27) performed significantly better in the RBC10 (p = 0.036) than the SSG (n = 5; 50 m time: 6.09 ± 0.13 s; RBC10: 7.09 ± 0.25). A very high correlation was attained between the RBC10 and the criterion measure, the SJ (r = 0.83). Additionally, RBC10 appeared to be correlated with 30, 50, 10-30 and 30-50 m sprint times (r = -0.52 to -0.60). This positive trend, however, was not observed for the DJ reactive strength index (trivial to moderate correlations). Good reliability was shown for the RBC10 and all sprint distances ("1.5% coefficient variation). Furthermore, all sprinters attained ground contact times of 0.12-0.18 s during the RBC10 which was indicative of fast stretch-shortening cycles during movement, suggesting that the RBC10 could be utilised to assess plyometric ability and enhance sprint performance. Overall, the RBC10 seems able to discriminate between the FSG and the SSG, indicating it has acceptable levels of validity and reliability.
Discovery and characterization of small molecules that target the GTPase Ral
Nature 2014 Nov 20;515(7527):443-7.PMID:25219851DOI:10.1038/nature13713.
The Ras-like GTPases RalA and RalB are important drivers of tumour growth and metastasis. Chemicals that block Ral function would be valuable as research tools and for cancer therapeutics. Here we used protein structure analysis and virtual screening to identify drug-like molecules that bind to a site on the GDP-bound form of Ral. The compounds RBC6, RBC8 and RBC10 inhibited the binding of Ral to its effector RALBP1, as well as inhibiting Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines. The binding of the RBC8 derivative BQU57 to RalB was confirmed by isothermal titration calorimetry, surface plasmon resonance and (1)H-(15)N transverse relaxation-optimized spectroscopy (TROSY) NMR spectroscopy. RBC8 and BQU57 show selectivity for Ral relative to the GTPases Ras and RhoA and inhibit tumour xenograft growth to a similar extent to the depletion of Ral using RNA interference. Our results show the utility of structure-based discovery for the development of therapeutics for Ral-dependent cancers.